---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-043405"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T21:53:04.763364+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rapport hires Dr. Jeffrey Sevigny as CMO; Phase 2a data expected Q3 2025

## Summary
- Jeffrey Sevigny, former CMO at Prevail Therapeutics (Eli Lilly), appointed CMO effective immediately.
- Phase 2a trial of RAP-219 in refractory focal epilepsy to report topline results in Q3 2025.
- Phase 2a trial of RAP-219 in bipolar mania to initiate in Q3 2025 with data expected in H1 2027.
- Sevigny brings 15+ years experience from Roche, Biogen, Novartis, and Merck to lead clinical strategy.

## SEC filing metadata
- accession: 0001193125-25-043405
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312525043405/0001193125-25-043405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312525043405/d876788d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-043405
- JSON: https://secwatch.observer/filing/0001193125-25-043405.json
- Plain text: https://secwatch.observer/filing/0001193125-25-043405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.